{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:15:19Z","timestamp":1762506919181},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/cgt.2016.41","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T15:49:27Z","timestamp":1476460167000},"page":"355-364","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer"],"prefix":"10.1038","volume":"23","author":[{"given":"C M","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K L","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Falls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"BFcgt201641_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL . Talimogene Laherparepvec: first global approval. Drugs 2016; 76: 147\u2013154.","journal-title":"Drugs"},{"key":"BFcgt201641_CR2","first-page":"547","volume":"11","author":"J Shi","year":"2009","unstructured":"Shi J, Zheng D . An update on gene therapy in China. Curr Opin Mol Ther 2009; 11: 547\u2013553.","journal-title":"Curr Opin Mol Ther"},{"key":"BFcgt201641_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","volume":"6","author":"CC Heise","year":"1999","unstructured":"Heise CC, Williams A, Olesch J, Kirn DH . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6: 499\u2013504.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201641_CR4","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","volume":"21","author":"FF Lang","year":"2003","unstructured":"Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508\u20132518.","journal-title":"J Clin Oncol"},{"key":"BFcgt201641_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1089\/hum.2010.227","volume":"22","author":"E Smith","year":"2011","unstructured":"Smith E, Breznik J, Lichty BD . Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 2011; 22: 1053\u20131060.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201641_CR6","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-03-3753","volume":"64","author":"O Ebert","year":"2004","unstructured":"Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL . Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64: 3265\u20133270.","journal-title":"Cancer Res"},{"key":"BFcgt201641_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1525-0016(03)00092-3","volume":"7","author":"X Fu","year":"2003","unstructured":"Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X . Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748\u2013754.","journal-title":"Mol Ther"},{"key":"BFcgt201641_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/gt.2011.184","volume":"19","author":"S Guedan","year":"2011","unstructured":"Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 2011; 19: 1048\u20131057.","journal-title":"Gene Ther"},{"key":"BFcgt201641_CR9","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1158\/1535-7163.MCT-06-0790","volume":"6","author":"D Hoffmann","year":"2007","unstructured":"Hoffmann D, Bayer W, Grunwald T, Wildner O . Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer. Mol Cancer Ther 2007; 6: 1942\u20131950.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201641_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1089\/10430340152710504","volume":"12","author":"H Li","year":"2001","unstructured":"Li H, Haviv YS, Derdeyn CA, Lam J, Coolidge C, Hunter E et al. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001; 12: 2155\u20132165.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201641_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12013-014-9835-5","volume":"69","author":"B Zhu","year":"2014","unstructured":"Zhu B, Yang JR, Fu XP, Jiang YQ . Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma. Cell Biochem Biophys 2014; 69: 577\u2013582.","journal-title":"Cell Biochem Biophys"},{"key":"BFcgt201641_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3748\/wjg.v13.i22.3063","volume":"13","author":"D Hoffmann","year":"2007","unstructured":"Hoffmann D, Bayer W, Wildner O . In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines. World J Gastroenterol 2007; 13: 3063\u20133070.","journal-title":"World J Gastroenterol"},{"key":"BFcgt201641_CR13","first-page":"673","volume":"20","author":"D Hoffmann","year":"2007","unstructured":"Hoffmann D, Bayer W, Wildner O . Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. Int J Mol Med 2007; 20: 673\u2013681.","journal-title":"Int J Mol Med"},{"key":"BFcgt201641_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/bjc.2011.577","volume":"106","author":"GR Simpson","year":"2012","unstructured":"Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer 2012; 106: 496\u2013507.","journal-title":"Br J Cancer"},{"key":"BFcgt201641_CR15","doi-asserted-by":"publisher","first-page":"10926","DOI":"10.1128\/JVI.00862-11","volume":"85","author":"RS Noyce","year":"2011","unstructured":"Noyce RS, Taylor K, Ciechonska M, Collins SE, Duncan R, Mossman KL . Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response. J Virol 2011; 85: 10926\u201310931.","journal-title":"J Virol"},{"key":"BFcgt201641_CR16","first-page":"6566","volume":"62","author":"AR Bateman","year":"2002","unstructured":"Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6566\u20136578.","journal-title":"Cancer Res"},{"key":"BFcgt201641_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.gt.3302609","volume":"13","author":"F Errington","year":"2006","unstructured":"Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13: 138\u2013149.","journal-title":"Gene Ther"},{"key":"BFcgt201641_CR18","first-page":"5495","volume":"62","author":"E Linardakis","year":"2002","unstructured":"Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002; 62: 5495\u20135504.","journal-title":"Cancer Res"},{"key":"BFcgt201641_CR19","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1128\/JVI.78.8.4342-4351.2004","volume":"78","author":"JA Corcoran","year":"2004","unstructured":"Corcoran JA, Duncan R . Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell\u2013cell fusion. J Virol 2004; 78: 4342\u20134351.","journal-title":"J Virol"},{"key":"BFcgt201641_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.virol.2003.10.025","volume":"319","author":"R Duncan","year":"2004","unstructured":"Duncan R, Corcoran J, Shou J, Stoltz D . Reptilian reovirus: a new fusogenic orthoreovirus species. Virology 2004; 319: 131\u2013140.","journal-title":"Virology"},{"key":"BFcgt201641_CR21","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1128\/JVI.79.13.8090-8100.2005","volume":"79","author":"J Salsman","year":"2005","unstructured":"Salsman J, Top D, Boutilier J, Duncan R . Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol 2005; 79: 8090\u20138100.","journal-title":"J Virol"},{"key":"BFcgt201641_CR22","doi-asserted-by":"publisher","first-page":"e1000331","DOI":"10.1371\/journal.ppat.1000331","volume":"5","author":"D Top","year":"2009","unstructured":"Top D, Barry C, Racine T, Ellis CL, Duncan R . Enhanced fusion pore expansion mediated by the trans-acting Endodomain of the reovirus FAST proteins. PLoS Pathogens 2009; 5: e1000331.","journal-title":"PLoS Pathogens"},{"key":"BFcgt201641_CR23","doi-asserted-by":"publisher","first-page":"e0151516","DOI":"10.1371\/journal.pone.0151516","volume":"11","author":"CM Wong","year":"2016","unstructured":"Wong CM, Poulin KL, Tong G, Christou C, Kennedy MA, Falls T et al. Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer. PLoS One 2016; 11: e0151516.","journal-title":"PLoS One"},{"key":"BFcgt201641_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/JVI.01921-08","volume":"83","author":"CW Brown","year":"2009","unstructured":"Brown CW, Stephenson KB, Hanson S, Kucharczyk M, Duncan R, Bell JC et al. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 2009; 83: 552\u2013561.","journal-title":"J Virol"},{"key":"BFcgt201641_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/mt.2010.44","volume":"18","author":"F Le Boeuf","year":"2010","unstructured":"Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010; 18: 888\u2013895.","journal-title":"Mol Ther"},{"key":"BFcgt201641_CR26","doi-asserted-by":"publisher","first-page":"10074","DOI":"10.1128\/JVI.02665-09","volume":"84","author":"KL Poulin","year":"2010","unstructured":"Poulin KL, Lanthier RM, Smith AC, Christou C, Risco Quiroz M, Powell KL et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010; 84: 10074\u201310086.","journal-title":"J Virol"},{"key":"BFcgt201641_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.virol.2011.09.004","volume":"420","author":"KL Poulin","year":"2011","unstructured":"Poulin KL, Tong G, Vorobyova O, Pool M, Kothary R, Parks RJ . Use of Cre\/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX. Virology 2011; 420: 146\u2013155.","journal-title":"Virology"},{"key":"BFcgt201641_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.virol.2014.08.026","volume":"468\u2013470C","author":"ER McFall","year":"2014","unstructured":"McFall ER, Murray LM, Lunde JA, Jasmin BJ, Kothary R, Parks RJ . A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice. Virology 2014; 468\u2013470C: 444\u2013453.","journal-title":"Virology"},{"key":"BFcgt201641_CR29","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1073\/pnas.082243699","volume":"99","author":"RE Campbell","year":"2002","unstructured":"Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A 2002; 99: 7877\u20137882.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFcgt201641_CR30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/nbt1037","volume":"22","author":"NC Shaner","year":"2004","unstructured":"Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY . Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567\u20131572.","journal-title":"Nat Biotechnol"},{"key":"BFcgt201641_CR31","first-page":"pdb prot5011","volume":"2009","author":"PJ Ross","year":"2009","unstructured":"Ross PJ, Parks RJ . Construction and characterization of adenovirus vectors. CSH Protoc 2009; 2009: pdb prot5011.","journal-title":"CSH Protoc"},{"key":"BFcgt201641_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263\u2013275.","journal-title":"Cancer Cell"},{"key":"BFcgt201641_CR33","doi-asserted-by":"publisher","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","volume":"93","author":"RJ Parks","year":"1996","unstructured":"Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL . A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565\u201313570.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFcgt201641_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1099\/vir.0.026013-0","volume":"92","author":"JA Corcoran","year":"2011","unstructured":"Corcoran JA, Clancy EK, Duncan R . Homomultimerization of the reovirus p14 fusion-associated small transmembrane protein during transit through the ER\u2013Golgi complex secretory pathway. J Gen Virol 2011; 92: 162\u2013166.","journal-title":"J Gen Virol"},{"key":"BFcgt201641_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.gt.3300508","volume":"4","author":"JL Bramson","year":"1997","unstructured":"Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069\u20131076.","journal-title":"Gene Ther"},{"key":"BFcgt201641_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/hum.1997.8.1-37","volume":"8","author":"S Worgall","year":"1997","unstructured":"Worgall S, Wolff G, Falck-Pedersen E, Crystal RG . Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37\u201344.","journal-title":"Hum Gene Ther"},{"issue":"Pt 7","key":"BFcgt201641_CR37","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1099\/0022-1317-78-7-1653","volume":"78","author":"CL Addison","year":"1997","unstructured":"Addison CL, Hitt M, Kunsken D, Graham FL . Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol. 1997; 78 (Pt 7): 1653\u20131661.","journal-title":"J Gen Virol."},{"key":"BFcgt201641_CR38","first-page":"6396","volume":"60","author":"H Higuchi","year":"2000","unstructured":"Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ . Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 2000; 60: 6396\u20136402.","journal-title":"Cancer Res"},{"key":"BFcgt201641_CR39","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/0008-5472.CAN-04-2874","volume":"65","author":"JD Lewis","year":"2005","unstructured":"Lewis JD, Shearer MH, Kennedy RC, Bright RK . Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases. Cancer Res 2005; 65: 2938\u20132946.","journal-title":"Cancer Res"},{"key":"BFcgt201641_CR40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2741\/1604","volume":"10","author":"MD Weitzman","year":"2005","unstructured":"Weitzman MD . Functions of the adenovirus E4 proteins and their impact on viral vectors. Front Biosci 2005; 10: 1106\u20131117.","journal-title":"Front Biosci"},{"key":"BFcgt201641_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1083\/jcb.140.3.637","volume":"140","author":"JN Lavoie","year":"1998","unstructured":"Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC . E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 1998; 140: 637\u2013645.","journal-title":"J Cell Biol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cgt201641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201641","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:14:12Z","timestamp":1684415652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFcgt201641"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.41","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"13 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}